"Pfizer's Rollercoaster Ride: From Glory to Struggles, What's Next for the Biopharma Giant?"
Pfizer CEO Albert Bourla has been named the worst biopharma CEO of 2023 due to strategic missteps, financial miscalculations, and scientific setbacks that have led to a deep crisis for the company. Pfizer's shares have fallen 50% this year, erasing nearly $140 billion in market value, as Covid product sales have evaporated and the company struggles to fill the gap with aging medicines and underperforming drugs and vaccines. Bourla has an opportunity to turn things around with the recent acquisition of cancer drugmaker Seagen, but if the company doesn't see success, he may not be around to make the list next year. Other CEOs on the worst list include Chaim Lebovits of BrainStorm Cell Therapeutics, Antony Mattessich of Ocular Therapeutix, Dennis Lanfear of Coherus Biosciences, and Francis DeSouza of Illumina.